AOD-9604

Controlled human trials · larger obesity trial negative.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

AOD-9604 is a modified growth-hormone fragment developed as a potential obesity treatment. It was intended to separate fat-related activity from other growth-hormone effects, but that design goal did not establish clinically meaningful weight loss. [1]

02 Potential benefits

Investigated as a modified growth-hormone fragment for obesity. Designed to explore fat-metabolism effects without full GH activity. [1]

03 Evidence & its limits

Human trials exist, so describing AOD-9604 as merely untested misses the central finding: the larger oral trial failed its weight-loss endpoint. Those data also do not establish benefit or safety for subcutaneous products sold for fat loss. [1]

04 Risks & unknowns

No FDA-approved obesity indication. Clinical development did not establish the broad claims now made online. [1]

05 Status & scope

No FDA-approved obesity indication. [1]

06 The question to ask

Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates
[2] FDA briefing on AOD-9604, December 2024

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.